Aptadir Therapeutics is a biotechnology company based in Milan, Italy, specializing in the development of RNA inhibitor-based therapeutics. The firm focuses on creating novel treatments for intractable cancers and genetic disorders.
Subscribe to see Aptadir Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aptadir Therapeutics is a biotechnology company headquartered in Milan, Italy. It has raised at least $46.6M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $45M in September 2026. Xcout tracks 1 named person at Aptadir Therapeutics, including Giovanni Amabile (CEO and Founder).
As of 16 November 2026. Source: Xcout Intel.
At least $46.6M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $45M | 14 named | |
| Pre-Seed | $1.6M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 12 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of Aptadir Therapeutics's closest competitors — see the full list of competitors and alternatives →
Guardian Therapeutics, LLC is a biotechnology company that researches and develops aptamer-based therapeutics and drug conjugates. The company engineers drug-like aptamers for targeted treatments across multiple therapeutic areas, including hematology, gastroenterology, dermatology, and oncology.
AAVantgarde Bio is an Italian biotechnology company developing adeno-associated virus (AAV) gene therapies for rare genetic diseases, including conditions caused by genes too large to fit into a single AAV vector. Its technology uses dual-AAV approaches to deliver larger therapeutic genes, serving patients with serious inherited disorders and the clinicians who treat them.
Ceptur Therapeutics, Inc. is a private biotechnology company headquartered in Hillsborough, New Jersey, focused on developing targeted oligonucleotide therapeutics.
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Aptadir Therapeutics? Suggest a correction · Work at Aptadir Therapeutics? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.